173 related articles for article (PubMed ID: 12753730)
1. Development of liposomal polyene antibiotics: an historical perspective.
Ng AW; Wasan KM; Lopez-Berestein G
J Pharm Pharm Sci; 2003; 6(1):67-83. PubMed ID: 12753730
[TBL] [Abstract][Full Text] [Related]
2. Polyene antibiotics: relative degrees of in vitro cytotoxicity and potential effects on tubule phospholipid and ceramide content.
Zager RA
Am J Kidney Dis; 2000 Aug; 36(2):238-49. PubMed ID: 10922301
[TBL] [Abstract][Full Text] [Related]
3. Liposomal polyene antibiotics.
Ng AW; Wasan KM; Lopez-Berestein G
Methods Enzymol; 2005; 391():304-13. PubMed ID: 15721388
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
Chakraborty KK; Naik SR
J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
[TBL] [Abstract][Full Text] [Related]
5. Lipid-based antifungal agents: a concise overview.
Arikan S
Cell Mol Biol Lett; 2002; 7(3):919-22. PubMed ID: 12378276
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro studies on liposomal formulations of amphotericin B and its derivative, N-methyl-N-D-fructosyl amphotericin B methyl ester (MFAME).
Cybulska B; Kupczyk K; Szlinder-Richert J; Borowski E
Acta Biochim Pol; 2002; 49(1):67-75. PubMed ID: 12136958
[TBL] [Abstract][Full Text] [Related]
7. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections.
Sachs-Barrable K; Lee SD; Wasan EK; Thornton SJ; Wasan KM
Adv Drug Deliv Rev; 2008 Mar; 60(6):692-701. PubMed ID: 18053611
[TBL] [Abstract][Full Text] [Related]
8. Molecular modelling of membrane activity of amphotericin B, a polyene macrolide antifungal antibiotic.
Baginski M; Sternal K; Czub J; Borowski E
Acta Biochim Pol; 2005; 52(3):655-8. PubMed ID: 16086075
[TBL] [Abstract][Full Text] [Related]
9. Liposomal drug delivery system from laboratory to clinic.
Kshirsagar NA; Pandya SK; Kirodian GB; Sanath S
J Postgrad Med; 2005; 51 Suppl 1():S5-15. PubMed ID: 16519249
[TBL] [Abstract][Full Text] [Related]
10. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
11. The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis.
Thornton SJ; Wasan KM
Expert Opin Drug Deliv; 2009 Mar; 6(3):271-84. PubMed ID: 19327044
[TBL] [Abstract][Full Text] [Related]
12. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
13. Liposomal amphotericin B: clinical experience and perspectives.
Gibbs WJ; Drew RH; Perfect JR
Expert Rev Anti Infect Ther; 2005 Apr; 3(2):167-81. PubMed ID: 15918775
[TBL] [Abstract][Full Text] [Related]
14. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
15. Lipid formulations of polyene antifungal drugs and attenuation of associated nephrotoxicity.
Razzaque MS; Hossain MA; Ahsan N; Taguchi T
Nephron; 2001 Nov; 89(3):251-4. PubMed ID: 11598385
[TBL] [Abstract][Full Text] [Related]
16. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
17. Selective toxicity and enhanced therapeutic index of liposomal polyene antibiotics in systemic fungal infections.
Juliano RL; Lopez-Berestein G; Hopfer R; Mehta R; Mehta K; Mills K
Ann N Y Acad Sci; 1985; 446():390-402. PubMed ID: 3860162
[TBL] [Abstract][Full Text] [Related]
18. [Photostability of antifungal agents. 2. Photostability of polyene antibiotics].
Thoma K; Kübler N
Pharmazie; 1997 Apr; 52(4):294-302. PubMed ID: 9190607
[TBL] [Abstract][Full Text] [Related]
19. [Impact on renal function of an early switch from conventional to liposomal amphotericin B formulation in the empirical treatment of fungal infections].
Isnard F; Tilleul P; Laporte JP; Chevallier P; Pigneux A; Lafuma A; Monchecourt F; Mahi L; Deray G
Med Mal Infect; 2008 Apr; 38(4):208-14. PubMed ID: 18191521
[TBL] [Abstract][Full Text] [Related]
20. Amphotericin B formulations and drug targeting.
Torrado JJ; Espada R; Ballesteros MP; Torrado-Santiago S
J Pharm Sci; 2008 Jul; 97(7):2405-25. PubMed ID: 17893903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
